Sun Pharma Q2 net falls 46.5% on Protonix provision

Sun Pharmaceutical Industries reported a 46.5 percent drop in quarterly net profit after it set aside Rs 5.84 billion towards a possible compensation in a patent dispute case related to drug Protonix.

The Mumbai-based drugmaker said consolidated net profit fell to Rs 3.2 billion during fiscal second quarter ended September from Rs 5.98 billion a year earlier. Net sales rose 40.2 percent to Rs 26.57 billion.

Analysts had estimated the net profit at Rs 7.68 billion, according to Thomson Reuters I/B/E/S.

EDITORIAL OF THE DAY

  • Allow 100 per cent FDI in asset reconstruction companies

    The asset reconstruction business is 13 years old and still struggling like a toddler.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

Sarthak Raychaudhuri

vice-president, HR, Asia South Whirlpool of India

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

TODAY'S COLUMNS

Arun Nigavekar

Moocs will not replace traditional education

I am revisiting the topic of massive open online course ...

Rajgopal Nidamboor

From complexity to prudent adaptability

It is a travesty that a host of new, strikingly ...

Dharmendra Khandal

Creepy, you say? That’s merely ophidiphobia

Snakes are the earliest predators in the life of the ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture